SlideShare a Scribd company logo
1 of 49
Download to read offline
Impact of measurement error on positive controls
Rosa Gini
Agenzia regionale di sanit`a della Toscana, Florence, Italy
Advances in Precision and Personalized Medicine, SAMSI
March 14-15, 2019
Disclosure
I am employee of Agenzia regionale di sanit`a della Toscana, a public
agency which conducts pharmacoepi studies compliant with the
Code of Conduct of the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance
Measurement error is one of the main topics of my research
Motivation
You take the blue pill, the story ends, you wake
up in your bed and believe whatever you want
to believe. You take the red pill, you stay in
Wonderland, and I show you how deep the
rabbit hole goes. Remember, all Iā€™m oļ¬€ering is
the truth, nothing more.
Morpheus to Neo
Matrix, directed by The Wachowskis
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
From assumptions we know the observed
diļ¬€erence is an artefact: the true RR is 1
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
ā€œIf we now add an additional n simulated occurrences
[. . . ] we have doubled the riskā€
(Schuemie et al, 2018, PNAS)
Building positive controls
from negative controls
Treated with A Treated with B
Building positive controls
from negative controls
Treated with A Treated with B
If phenotype in A has low sensitivity, RR of
positive control is lower than 2
Building positive controls
from negative controls
Treated with A Treated with B
If phenotype in A has low PPV, RR of
positive control is higher than 2
Formula for expected RR
when simulated outcomes are injected at random
1
1.5
2
3
20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100
p=1% p=5% p=10%
50%
75%
100%
PPV
RR
Sensitivity (%)
RR = 1 +
1
kv
1 āˆ’ p
1 āˆ’ p
kv
p true frequency
po observed frequency
v positive predictive value
k reciprocal of sensitivity
in those treated with A
Formula for expected RR
when simulated outcomes are injected at random
1
1.5
2
3
20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100
p=1% p=5% p=10%
50%
75%
100%
PPV
RR
Sensitivity (%)
With random injection, RR of positive control
is only 2 if the phenotype of the negative
control has PPV=sensitivity in those treated
with A
Questions
Is this RR signiļ¬cantly diļ¬€erent from 2 in real
life?
Questions
Is this RR signiļ¬cantly diļ¬€erent from 2 in real
life?
How can this formula be applied at all, as we
normally do not have p, v, k?
Reminder
RR = 1 +
1
kv
1 āˆ’ p
1 āˆ’ p
kv
p true frequency
po observed frequency
v positive predictive value
k reciprocal of sensitivity
in those treated with A
Reminder
RR = 1 +
1
kv
1 āˆ’ p
1 āˆ’ p
kv
p true frequency
po observed frequency
v positive predictive value
k reciprocal of sensitivity
in those treated with A
p = pokv
Estimates of validity without a gold standard in
multidatabase studies
OHDSI Europe Symposium. Rotterdam, The Netherlands. March 23rd
-24th
, 2018.Disclosure This research received support from the Innovative Medicines Joint Undertaking under ADVANCE grant agreement Nr: 115557
Interpreting the effect of different concept sets, data domains and data provenances in cohorts from heterogeneous European data
sources: examples of component strategy application from the EMIF and the ADVANCE projects
Rosa Gini1
, Giuseppe Roberto1
, Caitlin Dodd2
, Kaatje Bollaerts3
, Alessandro Pasqua4
, Lars Pedersen5
, Miguel Angel Mayer6
, Ron Herings7
, David Ansell8
, Sulev Reisberg9
, Lara Tramontan10
, Gino Picelli11
, Consuelo Huerta12
, Elisa Martin-Merino12
, Talita Duarte-Salles13
,
Gianfranco Spiteri14
, Emmanouela Sdona14
, Paul Avillach15
, Peter Rijnbeek2
, Miriam Sturkenboom3,16
(1) Osservatorio di Epidemiologia, Agenzia regionale di sanit`a della Toscana, Florence, Italy; (2) Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands; (3) P-95, Leuven, Belgium; (4) Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy; (5) Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; (6) Hospital del Mar Medical Research Institute, Barcelona, Spain; (7) PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands; (8) The Health
Improvement Network, Cegedim Strategic Data Medical Research Ltd, London, UK; (9) Quretec, Software Technology and Applications Competence Center, University of Tartu, Tartu, Estonia; (10) Arsen`al.IT Consortium, Venetoā€™s Research Centre for eHealth Innovation, Treviso, Italy; (11) Pedianet, Padua, Italy; (12) Agencia Espaola de Medicamentos y Productos Sanitarios, Madrid, Spain; Institut Universitari dā€™InvestigaciĀ“o en AtenciĀ“o Primria (13) SIDIAP database, Primary Care Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; (14)
European Centre for Disease Prevention and Control, Sweden; (15) Department of Biomedical Informatics, Harvard Medical School & Childrenā€™s Hospital Informatics Program, Boston Childrenā€™s Hospital, Boston, MA, USA; (16) University Utrecht Medical Center, Utrecht, The Netherlands.
Identifying conditions in Europe
In a typical European data source based on
electronic records, data may be only collected
when a patient visits a primary care practice,
or only when patients visit a hospital for
inpatient care. When conducting a
multi-national, multi-database study in Europe,
medical conditions may be identiļ¬ed by
different case identiļ¬cation algorithms. A
process, called component strategy, was
developed and tested in two European
projects: EMIF and ADVANCE
Deļ¬ne component algorithms
Case-ļ¬nding algorithms are split in simpler algorithms,
each deļ¬ned by a triple. The Uniļ¬ed Medical Language
System (UMLS) was used to project concept sets to
local terminologies and free text keywords.
Data domain
involved, among
diagnosis, drug,
result from test, . . .
Concept set what
is the meaning of
the information that
is searched?
Data provenance
where was the
information
collected?
Extract, compose and compare
All the data sources extract all the available components and compute the occurrence of
components and of meaningful compositions in the study population. Occurence is
represented in the graphs below which enable comparisons. As an example of comparison:
when a composite algorithm A OR B is represented, the share of the pink bar accounts for the
share of subjects that would not be captured if B was not available: under suitable
assumptions, this provides an estimate of sensitivity of A.
Interpret and decide
Decide which data-source tailored composite
algorithm should be used. Obtain information
on validity. Design sensitivity analyses using
other algorithms.
An acute non-communicable disease:
acute myocardial infarction
AMI is a cardiac emergency, which requires
immediate medical attention and may lead to
death before access to a medical facility. Six data
sources from ļ¬ve European countries participating
in the EMIF project were used. The one year
cumulative incidence of new AMI cases in 2012
among subjects aged 45+, with at least two year of
look-back and no previous record of an AMI
diagnosis, was computed.
Component Concept set Data domain Data provenance
PC diagnosis (AMI) Diagnosis Primary care practice
Specialist diagnosis (AMI) Diagnosis Specialist practice
Inpatient diagnosis (AMI) Diagnosis Hospital
ER diagnosis (AMI) Diagnosis Emergency room
Cause of death (AMI) Diagnosis Death registry Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
Record linkage DBs could extract diagnoses from
inpatient, emergency care and death registry: they
probably captured most of the cases in the
underlying populations, although PPV of
diagnoses may vary according to data
provenance. Variability in cumulative incidence in
primary care DBs was possibly due to different
local recording habits, such as use of free text. In
one of the four primary care DBs, it was possible
to extract diagnoses from inpatient care as well:
assuming consistent PPV of primary and inpatient
care diagnoses, sensitivity of primary care records
was less than 60%.
An infectious disease:
bordetella pertussis
Pertussis is an infectious disease of the respiratory
tract, caused by the bacterium Bordetella
pertussis. Only a speciļ¬c laboratory tests can
ascertain the speciļ¬c microorganism responsible
for the infection. National notiļ¬cations of cases to
the public health authority are reported annually by
EU/EEA countries to the European Centre for
Disease Prevention and Control (ECDC). In ļ¬ve
databases participating in the ADVANCE project
incidence rates per 100,000 person-years during
the year 2012 and during the year 2014 were
computed in the population aged 0-14 years. The
incidence rates of the notiļ¬ed cases in the three
countries were computed from the ECDC
database.
Component Concept set Data domain Data provenance
PC diagnosis, speciļ¬c (Bordetella pertussis) Diagnosis Primary care practice
PC diagnosis, unspeciļ¬ed(Pertussis) Diagnosis Primary care practice
Laboratory results (Positive result from a
bordetella pertussis test)
Result from test Primary care practice
Symptoms (Symptoms of pertussis) Symptoms Primary care practice
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
In three data sources the IRs obtained by
combining cohorts of speciļ¬c and unspeciļ¬ed
diagnoses were compatible with the notiļ¬cation,
taking into account some misclassiļ¬cation in the
unspeciļ¬ed diagnosis. In one data source the
estimate was much higher, which might indicate
under -notiļ¬cation of suspected cases not ļ¬nally
conļ¬rmed to the relevant public health authority, or
a higher rate of misclassiļ¬cation in the unspeciļ¬ed
diagnosis in this data source. In another database,
a high number of cases was recorded in the
symptoms component, which in this data source
was identiļ¬ed by a very speciļ¬c string of free text
(ā€˜tos perusoideā€™) and the pooled estimate was
compatible with the notiļ¬cation. In all the
databases the percentage of cases recorded with
a speciļ¬c diagnosis was very low. The percentage
of cases conļ¬rmed by a record of a positive
diagnostic test was negligible in all the three
databases where this data domain was available.
A chronic disease:
type 2 diabetes mellitus
T2DM is a chronic metabolic disease which needs
diagnostic follow-up and, at a more advanced
stage, regular pharmaceutical treatment with
hypoglycemic drugs. T2DM care is typically
provided by primary care physicians. In six
population-based data sources from four
European countries participating in the EMIF
project prevalence of the cohorts at 1st January
2012 was computed in the adult population (16+).
Component Concept set Data domain Data provenance
PC diagnosis (T2DM) Diagnosis Primary care practice
Inpatient diagnosis (T2DM) Diagnosis Hospital
Laboratory results (Positive result from a
T2DM test)
Result from test Primary care practice
NIAD (Non-insulin antidiabetic
drugs)
Drug Primary care practice or
pharmacy NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
T2DM diagnoses in primary care could be
extracted from 3 data sources, where a validated
algorithm was also available. Between 54% and
76% of the cases detected by the validated
algorithms were users of NIAD. The record linkage
DBs could only extract diagnoses from inpatient
care, which yielded non-realistically low
prevalences. In those data sources, the
component of NIAD may be used to detect T2DM
cases: the sensitivity may be estimated between
54% and 76% from primary care DBs.
Application
In order to implement the component analysis in the OHDSI ecosystem, information on data provenance should be standardized. In
a ļ¬rst attempt, a simple classiļ¬cation in primary care practice, specialist practice, hospital, emergency room, and death registry, may
lead to interpretable information. The impact of using SNOMED CT instead of UMLS should be assessed. The possibility of
incorporating free text keywords in OHDSI concept sets should be explored in European data sources.
Conclusion
The nature of the disease under study is an important factor in the sensitivity and/or positive predictive value of a component. The
systematic creation and comparison of component-based algorithms could be useful in the OHDSI ecosystem to empower the
validity and efļ¬ciency of the data extraction. A systematic approach is needed in OHDSI to address the impact of the phenotypic
deļ¬nitions in a multi-database setting on study results.
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
observed: po = .0040
po = .0054
% = 89%
po = .0043
% = 85%
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
observed: po = .0040
po = .0054
% = 89%
po = .0043
% = 85%
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.87
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
observed: po = .0040
po = .0054
% = 89%
po = .0043
% = 85%
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.87
computed: p = .0046
An acute disease: acute myocardial infarction
Inpatient/ER OR death
PC OR inpatient diagnosis
Cause of death
ER diagnosis
Inpatient diagnosis
Specialist diagnosis
PC diagnosis
0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60
Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Cumulative incidence of new cases (per 10,000)
observed: po = .0040
po = .0054
% = 89%
po = .0043
% = 85%
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.87
computed: p = .0046
obtained RR: 1.9
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
observed:
po = .088
% = 55%
po = .064
po = .067
% = 77%
po = .041
po = .078
% = 53%
po = .042
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
observed:
po = .088
% = 55%
po = .064
po = .067
% = 77%
po = .041
po = .078
% = 53%
po = .042
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.62
v = 1
k = 1
.62
v = 1
k = 1
.62
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
observed:
po = .088
% = 55%
po = .064
po = .067
% = 77%
po = .041
po = .078
% = 53%
po = .042
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.62
v = 1
k = 1
.62
v = 1
k = 1
.62
computed: p = .103 p = .067 p = .067
A chronic disease: type 2 diabetes mellitus
NIAD OR validated algorithm
Validated algorithm
NIAD
Laboratory values
Inpatient diagnosis
PC diagnosis
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9
Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark
Left-hand side component only Both components Right-hand side component only
Prevalence (%)
observed:
po = .088
% = 55%
po = .064
po = .067
% = 77%
po = .041
po = .078
% = 53%
po = .042
assumed:
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
v = 1
k = 1
.62
v = 1
k = 1
.62
v = 1
k = 1
.62
computed: p = .103 p = .067 p = .067
obtained RR: 2.0 1.6 2.0 1.6 2.0 1.6
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
observed:
po = .00040
No = .00021
po = .00017
No = .00021
po = .00044
No = .00005
po = .00018
No = .00013
po = .00022
No = .00013
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
observed:
po = .00040
No = .00021
po = .00017
No = .00021
po = .00044
No = .00005
po = .00018
No = .00013
po = .00022
No = .00013
assumed:
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
observed:
po = .00040
No = .00021
po = .00017
No = .00021
po = .00044
No = .00005
po = .00018
No = .00013
po = .00022
No = .00013
assumed:
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
Ɨ Ɨ
Ɨ Ɨ
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
observed:
po = .00040
No = .00021
po = .00017
No = .00021
po = .00044
No = .00005
po = .00018
No = .00013
po = .00022
No = .00013
assumed:
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
Ɨ Ɨ
Ɨ Ɨ
computed: v = .53 v = .76 v = .60
An infectious disease: pertussis
PC diagnosis OR symptoms
Lab OR PC diagnosis
PC specific OR unspecified diagnosis
Laboratory results
PC diagnosis, unspecified
PC diagnosis, specific
0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50
Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B)
Left-hand side component only Both components Right-hand side component only
Notification
Incidence rate (per 100,000 person-years)
observed:
po = .00040
No = .00021
po = .00017
No = .00021
po = .00044
No = .00005
po = .00018
No = .00013
po = .00022
No = .00013
assumed:
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
k = 1
p = No
Ɨ Ɨ
Ɨ Ɨ
computed: v = .53 v = .76 v = .60
obtained RR: 2.9 2.3 2.7
Wrap up
Wrap up
Wrap up
Wrap up
Wrap up
Thanks

More Related Content

Similar to PMED: APPM Workshop: Impact of Measurement Error on Positive Controls - Rosa Gini, March 14, 2019

[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...
[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...
[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...DataScienceConferenc1
Ā 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisationSomya Solanki
Ā 
journal.pntd.0000877.PDF
journal.pntd.0000877.PDFjournal.pntd.0000877.PDF
journal.pntd.0000877.PDFOsamaAlsabaee2024
Ā 
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...CrimsonpublishersMedical
Ā 
Fetal monitoring rcog
Fetal monitoring rcogFetal monitoring rcog
Fetal monitoring rcogNorman Triantoro
Ā 
All cause mortality in treated hiv-infected
All cause mortality in treated hiv-infectedAll cause mortality in treated hiv-infected
All cause mortality in treated hiv-infectedAna Paula Bringel
Ā 
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdf
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdfGuidelines for the management of hospital-adquired pneumonia ERJ 2017.pdf
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdfDenisBacinschi2
Ā 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...Arete-Zoe, LLC
Ā 
Evaluating the Medical Literature
Evaluating the Medical LiteratureEvaluating the Medical Literature
Evaluating the Medical LiteratureClista Clanton
Ā 
Engineering better Health
Engineering better HealthEngineering better Health
Engineering better Health3GDR
Ā 
Pediatric Primary Care In Europe. The most appropriate medical professional ...
Pediatric Primary Care In Europe.  The most appropriate medical professional ...Pediatric Primary Care In Europe.  The most appropriate medical professional ...
Pediatric Primary Care In Europe. The most appropriate medical professional ...pediatricworld MSN
Ā 
Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...PUBLISHERJOURNAL
Ā 
Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...PUBLISHERJOURNAL
Ā 
Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Jean Jacques Bernatas
Ā 
Ignacio Previgliano - Argentina - Monday 28 - ICU and Organ Donation
Ignacio Previgliano -  Argentina - Monday 28 - ICU and Organ DonationIgnacio Previgliano -  Argentina - Monday 28 - ICU and Organ Donation
Ignacio Previgliano - Argentina - Monday 28 - ICU and Organ Donationincucai_isodp
Ā 

Similar to PMED: APPM Workshop: Impact of Measurement Error on Positive Controls - Rosa Gini, March 14, 2019 (20)

[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...
[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...
[DSC Europe 23] Stefan Zivkovic - Unlocking the Potential of Artificial Intel...
Ā 
Pharmacovigilance organisation
Pharmacovigilance organisationPharmacovigilance organisation
Pharmacovigilance organisation
Ā 
Validation of HAI-Net ICU data. Jacqui Reilly (UK)
Validation of HAI-Net ICU data. Jacqui Reilly (UK)Validation of HAI-Net ICU data. Jacqui Reilly (UK)
Validation of HAI-Net ICU data. Jacqui Reilly (UK)
Ā 
000010 tpi en vih
000010 tpi en vih000010 tpi en vih
000010 tpi en vih
Ā 
journal.pntd.0000877.PDF
journal.pntd.0000877.PDFjournal.pntd.0000877.PDF
journal.pntd.0000877.PDF
Ā 
Infections among people who inject drugs -- problem solved?
Infections among people who inject drugs -- problem solved?Infections among people who inject drugs -- problem solved?
Infections among people who inject drugs -- problem solved?
Ā 
Clinical epidemiology
Clinical epidemiologyClinical epidemiology
Clinical epidemiology
Ā 
Temprano trial nejm
Temprano trial nejmTemprano trial nejm
Temprano trial nejm
Ā 
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...
Crimson Publishers - The Use of Artificial Intelligence Methods in the Evalua...
Ā 
Fetal monitoring rcog
Fetal monitoring rcogFetal monitoring rcog
Fetal monitoring rcog
Ā 
All cause mortality in treated hiv-infected
All cause mortality in treated hiv-infectedAll cause mortality in treated hiv-infected
All cause mortality in treated hiv-infected
Ā 
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdf
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdfGuidelines for the management of hospital-adquired pneumonia ERJ 2017.pdf
Guidelines for the management of hospital-adquired pneumonia ERJ 2017.pdf
Ā 
The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...The value of real-world evidence for clinicians and clinical researchers in t...
The value of real-world evidence for clinicians and clinical researchers in t...
Ā 
Evaluating the Medical Literature
Evaluating the Medical LiteratureEvaluating the Medical Literature
Evaluating the Medical Literature
Ā 
Engineering better Health
Engineering better HealthEngineering better Health
Engineering better Health
Ā 
Pediatric Primary Care In Europe. The most appropriate medical professional ...
Pediatric Primary Care In Europe.  The most appropriate medical professional ...Pediatric Primary Care In Europe.  The most appropriate medical professional ...
Pediatric Primary Care In Europe. The most appropriate medical professional ...
Ā 
Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...
Ā 
Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...Evaluation factors contributing to the treatment default by tuberculosis pati...
Evaluation factors contributing to the treatment default by tuberculosis pati...
Ā 
Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.Surveillance of emerging diseases and networks.
Surveillance of emerging diseases and networks.
Ā 
Ignacio Previgliano - Argentina - Monday 28 - ICU and Organ Donation
Ignacio Previgliano -  Argentina - Monday 28 - ICU and Organ DonationIgnacio Previgliano -  Argentina - Monday 28 - ICU and Organ Donation
Ignacio Previgliano - Argentina - Monday 28 - ICU and Organ Donation
Ā 

More from The Statistical and Applied Mathematical Sciences Institute

More from The Statistical and Applied Mathematical Sciences Institute (20)

Causal Inference Opening Workshop - Latent Variable Models, Causal Inference,...
Causal Inference Opening Workshop - Latent Variable Models, Causal Inference,...Causal Inference Opening Workshop - Latent Variable Models, Causal Inference,...
Causal Inference Opening Workshop - Latent Variable Models, Causal Inference,...
Ā 
2019 Fall Series: Special Guest Lecture - 0-1 Phase Transitions in High Dimen...
2019 Fall Series: Special Guest Lecture - 0-1 Phase Transitions in High Dimen...2019 Fall Series: Special Guest Lecture - 0-1 Phase Transitions in High Dimen...
2019 Fall Series: Special Guest Lecture - 0-1 Phase Transitions in High Dimen...
Ā 
Causal Inference Opening Workshop - Causal Discovery in Neuroimaging Data - F...
Causal Inference Opening Workshop - Causal Discovery in Neuroimaging Data - F...Causal Inference Opening Workshop - Causal Discovery in Neuroimaging Data - F...
Causal Inference Opening Workshop - Causal Discovery in Neuroimaging Data - F...
Ā 
Causal Inference Opening Workshop - Smooth Extensions to BART for Heterogeneo...
Causal Inference Opening Workshop - Smooth Extensions to BART for Heterogeneo...Causal Inference Opening Workshop - Smooth Extensions to BART for Heterogeneo...
Causal Inference Opening Workshop - Smooth Extensions to BART for Heterogeneo...
Ā 
Causal Inference Opening Workshop - A Bracketing Relationship between Differe...
Causal Inference Opening Workshop - A Bracketing Relationship between Differe...Causal Inference Opening Workshop - A Bracketing Relationship between Differe...
Causal Inference Opening Workshop - A Bracketing Relationship between Differe...
Ā 
Causal Inference Opening Workshop - Testing Weak Nulls in Matched Observation...
Causal Inference Opening Workshop - Testing Weak Nulls in Matched Observation...Causal Inference Opening Workshop - Testing Weak Nulls in Matched Observation...
Causal Inference Opening Workshop - Testing Weak Nulls in Matched Observation...
Ā 
Causal Inference Opening Workshop - Difference-in-differences: more than meet...
Causal Inference Opening Workshop - Difference-in-differences: more than meet...Causal Inference Opening Workshop - Difference-in-differences: more than meet...
Causal Inference Opening Workshop - Difference-in-differences: more than meet...
Ā 
Causal Inference Opening Workshop - New Statistical Learning Methods for Esti...
Causal Inference Opening Workshop - New Statistical Learning Methods for Esti...Causal Inference Opening Workshop - New Statistical Learning Methods for Esti...
Causal Inference Opening Workshop - New Statistical Learning Methods for Esti...
Ā 
Causal Inference Opening Workshop - Bipartite Causal Inference with Interfere...
Causal Inference Opening Workshop - Bipartite Causal Inference with Interfere...Causal Inference Opening Workshop - Bipartite Causal Inference with Interfere...
Causal Inference Opening Workshop - Bipartite Causal Inference with Interfere...
Ā 
Causal Inference Opening Workshop - Bridging the Gap Between Causal Literatur...
Causal Inference Opening Workshop - Bridging the Gap Between Causal Literatur...Causal Inference Opening Workshop - Bridging the Gap Between Causal Literatur...
Causal Inference Opening Workshop - Bridging the Gap Between Causal Literatur...
Ā 
Causal Inference Opening Workshop - Some Applications of Reinforcement Learni...
Causal Inference Opening Workshop - Some Applications of Reinforcement Learni...Causal Inference Opening Workshop - Some Applications of Reinforcement Learni...
Causal Inference Opening Workshop - Some Applications of Reinforcement Learni...
Ā 
Causal Inference Opening Workshop - Bracketing Bounds for Differences-in-Diff...
Causal Inference Opening Workshop - Bracketing Bounds for Differences-in-Diff...Causal Inference Opening Workshop - Bracketing Bounds for Differences-in-Diff...
Causal Inference Opening Workshop - Bracketing Bounds for Differences-in-Diff...
Ā 
Causal Inference Opening Workshop - Assisting the Impact of State Polcies: Br...
Causal Inference Opening Workshop - Assisting the Impact of State Polcies: Br...Causal Inference Opening Workshop - Assisting the Impact of State Polcies: Br...
Causal Inference Opening Workshop - Assisting the Impact of State Polcies: Br...
Ā 
Causal Inference Opening Workshop - Experimenting in Equilibrium - Stefan Wag...
Causal Inference Opening Workshop - Experimenting in Equilibrium - Stefan Wag...Causal Inference Opening Workshop - Experimenting in Equilibrium - Stefan Wag...
Causal Inference Opening Workshop - Experimenting in Equilibrium - Stefan Wag...
Ā 
Causal Inference Opening Workshop - Targeted Learning for Causal Inference Ba...
Causal Inference Opening Workshop - Targeted Learning for Causal Inference Ba...Causal Inference Opening Workshop - Targeted Learning for Causal Inference Ba...
Causal Inference Opening Workshop - Targeted Learning for Causal Inference Ba...
Ā 
Causal Inference Opening Workshop - Bayesian Nonparametric Models for Treatme...
Causal Inference Opening Workshop - Bayesian Nonparametric Models for Treatme...Causal Inference Opening Workshop - Bayesian Nonparametric Models for Treatme...
Causal Inference Opening Workshop - Bayesian Nonparametric Models for Treatme...
Ā 
2019 Fall Series: Special Guest Lecture - Adversarial Risk Analysis of the Ge...
2019 Fall Series: Special Guest Lecture - Adversarial Risk Analysis of the Ge...2019 Fall Series: Special Guest Lecture - Adversarial Risk Analysis of the Ge...
2019 Fall Series: Special Guest Lecture - Adversarial Risk Analysis of the Ge...
Ā 
2019 Fall Series: Professional Development, Writing Academic Papersā€¦What Work...
2019 Fall Series: Professional Development, Writing Academic Papersā€¦What Work...2019 Fall Series: Professional Development, Writing Academic Papersā€¦What Work...
2019 Fall Series: Professional Development, Writing Academic Papersā€¦What Work...
Ā 
2019 GDRR: Blockchain Data Analytics - Machine Learning in/for Blockchain: Fu...
2019 GDRR: Blockchain Data Analytics - Machine Learning in/for Blockchain: Fu...2019 GDRR: Blockchain Data Analytics - Machine Learning in/for Blockchain: Fu...
2019 GDRR: Blockchain Data Analytics - Machine Learning in/for Blockchain: Fu...
Ā 
2019 GDRR: Blockchain Data Analytics - QuTrack: Model Life Cycle Management f...
2019 GDRR: Blockchain Data Analytics - QuTrack: Model Life Cycle Management f...2019 GDRR: Blockchain Data Analytics - QuTrack: Model Life Cycle Management f...
2019 GDRR: Blockchain Data Analytics - QuTrack: Model Life Cycle Management f...
Ā 

Recently uploaded

Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
Ā 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsKarinaGenton
Ā 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
Ā 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
Ā 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
Ā 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
Ā 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
Ā 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
Ā 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
Ā 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
Ā 
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
Ā 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
Ā 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
Ā 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
Ā 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersChitralekhaTherkar
Ā 
PSYCHIATRIC History collection FORMAT.pptx
PSYCHIATRIC   History collection FORMAT.pptxPSYCHIATRIC   History collection FORMAT.pptx
PSYCHIATRIC History collection FORMAT.pptxPoojaSen20
Ā 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
Ā 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
Ā 

Recently uploaded (20)

Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Ā 
Science 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its CharacteristicsScience 7 - LAND and SEA BREEZE and its Characteristics
Science 7 - LAND and SEA BREEZE and its Characteristics
Ā 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
Ā 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
Ā 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
Ā 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
Ā 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
Ā 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Ā 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
Ā 
Model Call Girl in Bikash Puri Delhi reach out to us at šŸ”9953056974šŸ”
Model Call Girl in Bikash Puri  Delhi reach out to us at šŸ”9953056974šŸ”Model Call Girl in Bikash Puri  Delhi reach out to us at šŸ”9953056974šŸ”
Model Call Girl in Bikash Puri Delhi reach out to us at šŸ”9953056974šŸ”
Ā 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
Ā 
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
ā€œOh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
Ā 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
Ā 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
Ā 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
Ā 
Micromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of PowdersMicromeritics - Fundamental and Derived Properties of Powders
Micromeritics - Fundamental and Derived Properties of Powders
Ā 
PSYCHIATRIC History collection FORMAT.pptx
PSYCHIATRIC   History collection FORMAT.pptxPSYCHIATRIC   History collection FORMAT.pptx
PSYCHIATRIC History collection FORMAT.pptx
Ā 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
Ā 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
Ā 
Model Call Girl in Tilak Nagar Delhi reach out to us at šŸ”9953056974šŸ”
Model Call Girl in Tilak Nagar Delhi reach out to us at šŸ”9953056974šŸ”Model Call Girl in Tilak Nagar Delhi reach out to us at šŸ”9953056974šŸ”
Model Call Girl in Tilak Nagar Delhi reach out to us at šŸ”9953056974šŸ”
Ā 

PMED: APPM Workshop: Impact of Measurement Error on Positive Controls - Rosa Gini, March 14, 2019

  • 1. Impact of measurement error on positive controls Rosa Gini Agenzia regionale di sanit`a della Toscana, Florence, Italy Advances in Precision and Personalized Medicine, SAMSI March 14-15, 2019
  • 2. Disclosure I am employee of Agenzia regionale di sanit`a della Toscana, a public agency which conducts pharmacoepi studies compliant with the Code of Conduct of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance Measurement error is one of the main topics of my research
  • 4. You take the blue pill, the story ends, you wake up in your bed and believe whatever you want to believe. You take the red pill, you stay in Wonderland, and I show you how deep the rabbit hole goes. Remember, all Iā€™m oļ¬€ering is the truth, nothing more. Morpheus to Neo Matrix, directed by The Wachowskis
  • 5. Building positive controls from negative controls Treated with A Treated with B
  • 6. Building positive controls from negative controls Treated with A Treated with B
  • 7. Building positive controls from negative controls Treated with A Treated with B From assumptions we know the observed diļ¬€erence is an artefact: the true RR is 1
  • 8. Building positive controls from negative controls Treated with A Treated with B
  • 9. Building positive controls from negative controls Treated with A Treated with B
  • 10. Building positive controls from negative controls Treated with A Treated with B
  • 11. Building positive controls from negative controls Treated with A Treated with B
  • 12. Building positive controls from negative controls Treated with A Treated with B ā€œIf we now add an additional n simulated occurrences [. . . ] we have doubled the riskā€ (Schuemie et al, 2018, PNAS)
  • 13. Building positive controls from negative controls Treated with A Treated with B
  • 14. Building positive controls from negative controls Treated with A Treated with B If phenotype in A has low sensitivity, RR of positive control is lower than 2
  • 15. Building positive controls from negative controls Treated with A Treated with B If phenotype in A has low PPV, RR of positive control is higher than 2
  • 16. Formula for expected RR when simulated outcomes are injected at random 1 1.5 2 3 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 p=1% p=5% p=10% 50% 75% 100% PPV RR Sensitivity (%) RR = 1 + 1 kv 1 āˆ’ p 1 āˆ’ p kv p true frequency po observed frequency v positive predictive value k reciprocal of sensitivity in those treated with A
  • 17. Formula for expected RR when simulated outcomes are injected at random 1 1.5 2 3 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 20 30 40 50 60 70 80 90 100 p=1% p=5% p=10% 50% 75% 100% PPV RR Sensitivity (%) With random injection, RR of positive control is only 2 if the phenotype of the negative control has PPV=sensitivity in those treated with A
  • 18. Questions Is this RR signiļ¬cantly diļ¬€erent from 2 in real life?
  • 19. Questions Is this RR signiļ¬cantly diļ¬€erent from 2 in real life? How can this formula be applied at all, as we normally do not have p, v, k?
  • 20. Reminder RR = 1 + 1 kv 1 āˆ’ p 1 āˆ’ p kv p true frequency po observed frequency v positive predictive value k reciprocal of sensitivity in those treated with A
  • 21. Reminder RR = 1 + 1 kv 1 āˆ’ p 1 āˆ’ p kv p true frequency po observed frequency v positive predictive value k reciprocal of sensitivity in those treated with A p = pokv
  • 22. Estimates of validity without a gold standard in multidatabase studies OHDSI Europe Symposium. Rotterdam, The Netherlands. March 23rd -24th , 2018.Disclosure This research received support from the Innovative Medicines Joint Undertaking under ADVANCE grant agreement Nr: 115557 Interpreting the effect of different concept sets, data domains and data provenances in cohorts from heterogeneous European data sources: examples of component strategy application from the EMIF and the ADVANCE projects Rosa Gini1 , Giuseppe Roberto1 , Caitlin Dodd2 , Kaatje Bollaerts3 , Alessandro Pasqua4 , Lars Pedersen5 , Miguel Angel Mayer6 , Ron Herings7 , David Ansell8 , Sulev Reisberg9 , Lara Tramontan10 , Gino Picelli11 , Consuelo Huerta12 , Elisa Martin-Merino12 , Talita Duarte-Salles13 , Gianfranco Spiteri14 , Emmanouela Sdona14 , Paul Avillach15 , Peter Rijnbeek2 , Miriam Sturkenboom3,16 (1) Osservatorio di Epidemiologia, Agenzia regionale di sanit`a della Toscana, Florence, Italy; (2) Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands; (3) P-95, Leuven, Belgium; (4) Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy; (5) Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; (6) Hospital del Mar Medical Research Institute, Barcelona, Spain; (7) PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands; (8) The Health Improvement Network, Cegedim Strategic Data Medical Research Ltd, London, UK; (9) Quretec, Software Technology and Applications Competence Center, University of Tartu, Tartu, Estonia; (10) Arsen`al.IT Consortium, Venetoā€™s Research Centre for eHealth Innovation, Treviso, Italy; (11) Pedianet, Padua, Italy; (12) Agencia Espaola de Medicamentos y Productos Sanitarios, Madrid, Spain; Institut Universitari dā€™InvestigaciĀ“o en AtenciĀ“o Primria (13) SIDIAP database, Primary Care Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain; (14) European Centre for Disease Prevention and Control, Sweden; (15) Department of Biomedical Informatics, Harvard Medical School & Childrenā€™s Hospital Informatics Program, Boston Childrenā€™s Hospital, Boston, MA, USA; (16) University Utrecht Medical Center, Utrecht, The Netherlands. Identifying conditions in Europe In a typical European data source based on electronic records, data may be only collected when a patient visits a primary care practice, or only when patients visit a hospital for inpatient care. When conducting a multi-national, multi-database study in Europe, medical conditions may be identiļ¬ed by different case identiļ¬cation algorithms. A process, called component strategy, was developed and tested in two European projects: EMIF and ADVANCE Deļ¬ne component algorithms Case-ļ¬nding algorithms are split in simpler algorithms, each deļ¬ned by a triple. The Uniļ¬ed Medical Language System (UMLS) was used to project concept sets to local terminologies and free text keywords. Data domain involved, among diagnosis, drug, result from test, . . . Concept set what is the meaning of the information that is searched? Data provenance where was the information collected? Extract, compose and compare All the data sources extract all the available components and compute the occurrence of components and of meaningful compositions in the study population. Occurence is represented in the graphs below which enable comparisons. As an example of comparison: when a composite algorithm A OR B is represented, the share of the pink bar accounts for the share of subjects that would not be captured if B was not available: under suitable assumptions, this provides an estimate of sensitivity of A. Interpret and decide Decide which data-source tailored composite algorithm should be used. Obtain information on validity. Design sensitivity analyses using other algorithms. An acute non-communicable disease: acute myocardial infarction AMI is a cardiac emergency, which requires immediate medical attention and may lead to death before access to a medical facility. Six data sources from ļ¬ve European countries participating in the EMIF project were used. The one year cumulative incidence of new AMI cases in 2012 among subjects aged 45+, with at least two year of look-back and no previous record of an AMI diagnosis, was computed. Component Concept set Data domain Data provenance PC diagnosis (AMI) Diagnosis Primary care practice Specialist diagnosis (AMI) Diagnosis Specialist practice Inpatient diagnosis (AMI) Diagnosis Hospital ER diagnosis (AMI) Diagnosis Emergency room Cause of death (AMI) Diagnosis Death registry Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000) Record linkage DBs could extract diagnoses from inpatient, emergency care and death registry: they probably captured most of the cases in the underlying populations, although PPV of diagnoses may vary according to data provenance. Variability in cumulative incidence in primary care DBs was possibly due to different local recording habits, such as use of free text. In one of the four primary care DBs, it was possible to extract diagnoses from inpatient care as well: assuming consistent PPV of primary and inpatient care diagnoses, sensitivity of primary care records was less than 60%. An infectious disease: bordetella pertussis Pertussis is an infectious disease of the respiratory tract, caused by the bacterium Bordetella pertussis. Only a speciļ¬c laboratory tests can ascertain the speciļ¬c microorganism responsible for the infection. National notiļ¬cations of cases to the public health authority are reported annually by EU/EEA countries to the European Centre for Disease Prevention and Control (ECDC). In ļ¬ve databases participating in the ADVANCE project incidence rates per 100,000 person-years during the year 2012 and during the year 2014 were computed in the population aged 0-14 years. The incidence rates of the notiļ¬ed cases in the three countries were computed from the ECDC database. Component Concept set Data domain Data provenance PC diagnosis, speciļ¬c (Bordetella pertussis) Diagnosis Primary care practice PC diagnosis, unspeciļ¬ed(Pertussis) Diagnosis Primary care practice Laboratory results (Positive result from a bordetella pertussis test) Result from test Primary care practice Symptoms (Symptoms of pertussis) Symptoms Primary care practice PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) In three data sources the IRs obtained by combining cohorts of speciļ¬c and unspeciļ¬ed diagnoses were compatible with the notiļ¬cation, taking into account some misclassiļ¬cation in the unspeciļ¬ed diagnosis. In one data source the estimate was much higher, which might indicate under -notiļ¬cation of suspected cases not ļ¬nally conļ¬rmed to the relevant public health authority, or a higher rate of misclassiļ¬cation in the unspeciļ¬ed diagnosis in this data source. In another database, a high number of cases was recorded in the symptoms component, which in this data source was identiļ¬ed by a very speciļ¬c string of free text (ā€˜tos perusoideā€™) and the pooled estimate was compatible with the notiļ¬cation. In all the databases the percentage of cases recorded with a speciļ¬c diagnosis was very low. The percentage of cases conļ¬rmed by a record of a positive diagnostic test was negligible in all the three databases where this data domain was available. A chronic disease: type 2 diabetes mellitus T2DM is a chronic metabolic disease which needs diagnostic follow-up and, at a more advanced stage, regular pharmaceutical treatment with hypoglycemic drugs. T2DM care is typically provided by primary care physicians. In six population-based data sources from four European countries participating in the EMIF project prevalence of the cohorts at 1st January 2012 was computed in the adult population (16+). Component Concept set Data domain Data provenance PC diagnosis (T2DM) Diagnosis Primary care practice Inpatient diagnosis (T2DM) Diagnosis Hospital Laboratory results (Positive result from a T2DM test) Result from test Primary care practice NIAD (Non-insulin antidiabetic drugs) Drug Primary care practice or pharmacy NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%) T2DM diagnoses in primary care could be extracted from 3 data sources, where a validated algorithm was also available. Between 54% and 76% of the cases detected by the validated algorithms were users of NIAD. The record linkage DBs could only extract diagnoses from inpatient care, which yielded non-realistically low prevalences. In those data sources, the component of NIAD may be used to detect T2DM cases: the sensitivity may be estimated between 54% and 76% from primary care DBs. Application In order to implement the component analysis in the OHDSI ecosystem, information on data provenance should be standardized. In a ļ¬rst attempt, a simple classiļ¬cation in primary care practice, specialist practice, hospital, emergency room, and death registry, may lead to interpretable information. The impact of using SNOMED CT instead of UMLS should be assessed. The possibility of incorporating free text keywords in OHDSI concept sets should be explored in European data sources. Conclusion The nature of the disease under study is an important factor in the sensitivity and/or positive predictive value of a component. The systematic creation and comparison of component-based algorithms could be useful in the OHDSI ecosystem to empower the validity and efļ¬ciency of the data extraction. A systematic approach is needed in OHDSI to address the impact of the phenotypic deļ¬nitions in a multi-database setting on study results.
  • 23. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000)
  • 24. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000)
  • 25. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000)
  • 26. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000) observed: po = .0040 po = .0054 % = 89% po = .0043 % = 85%
  • 27. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000) observed: po = .0040 po = .0054 % = 89% po = .0043 % = 85% assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .87
  • 28. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000) observed: po = .0040 po = .0054 % = 89% po = .0043 % = 85% assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .87 computed: p = .0046
  • 29. An acute disease: acute myocardial infarction Inpatient/ER OR death PC OR inpatient diagnosis Cause of death ER diagnosis Inpatient diagnosis Specialist diagnosis PC diagnosis 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Primary care DB, Spain Hospital DB, Spain Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Cumulative incidence of new cases (per 10,000) observed: po = .0040 po = .0054 % = 89% po = .0043 % = 85% assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .87 computed: p = .0046 obtained RR: 1.9
  • 30. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%)
  • 31. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%)
  • 32. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%)
  • 33. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%) observed: po = .088 % = 55% po = .064 po = .067 % = 77% po = .041 po = .078 % = 53% po = .042
  • 34. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%) observed: po = .088 % = 55% po = .064 po = .067 % = 77% po = .041 po = .078 % = 53% po = .042 assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .62 v = 1 k = 1 .62 v = 1 k = 1 .62
  • 35. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%) observed: po = .088 % = 55% po = .064 po = .067 % = 77% po = .041 po = .078 % = 53% po = .042 assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .62 v = 1 k = 1 .62 v = 1 k = 1 .62 computed: p = .103 p = .067 p = .067
  • 36. A chronic disease: type 2 diabetes mellitus NIAD OR validated algorithm Validated algorithm NIAD Laboratory values Inpatient diagnosis PC diagnosis 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 Primary care DB, Italy Record linkage DB, Italy Primary care DB, The Netherlands Record linkage DB, The Netherlands Primary care DB, UK Record linkage DB, Denmark Left-hand side component only Both components Right-hand side component only Prevalence (%) observed: po = .088 % = 55% po = .064 po = .067 % = 77% po = .041 po = .078 % = 53% po = .042 assumed: v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 v = 1 k = 1 .62 v = 1 k = 1 .62 v = 1 k = 1 .62 computed: p = .103 p = .067 p = .067 obtained RR: 2.0 1.6 2.0 1.6 2.0 1.6
  • 37. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years)
  • 38. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years)
  • 39. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years)
  • 40. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) observed: po = .00040 No = .00021 po = .00017 No = .00021 po = .00044 No = .00005 po = .00018 No = .00013 po = .00022 No = .00013
  • 41. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) observed: po = .00040 No = .00021 po = .00017 No = .00021 po = .00044 No = .00005 po = .00018 No = .00013 po = .00022 No = .00013 assumed: k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No
  • 42. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) observed: po = .00040 No = .00021 po = .00017 No = .00021 po = .00044 No = .00005 po = .00018 No = .00013 po = .00022 No = .00013 assumed: k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No Ɨ Ɨ Ɨ Ɨ
  • 43. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) observed: po = .00040 No = .00021 po = .00017 No = .00021 po = .00044 No = .00005 po = .00018 No = .00013 po = .00022 No = .00013 assumed: k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No Ɨ Ɨ Ɨ Ɨ computed: v = .53 v = .76 v = .60
  • 44. An infectious disease: pertussis PC diagnosis OR symptoms Lab OR PC diagnosis PC specific OR unspecified diagnosis Laboratory results PC diagnosis, unspecified PC diagnosis, specific 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 0 10 20 30 40 50 Primary care DB, Spain (A) Primary care DB, Spain (B) Primary care DB, Italy Primary care DB, UK (A) Primary care DB, UK (B) Left-hand side component only Both components Right-hand side component only Notification Incidence rate (per 100,000 person-years) observed: po = .00040 No = .00021 po = .00017 No = .00021 po = .00044 No = .00005 po = .00018 No = .00013 po = .00022 No = .00013 assumed: k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No k = 1 p = No Ɨ Ɨ Ɨ Ɨ computed: v = .53 v = .76 v = .60 obtained RR: 2.9 2.3 2.7